MedCity News
MorphoSys to buy Constellation Pharma in a $1.7B bet on epigenetic cancer drugs
MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.
Shares0
MorphoSys, a biotech that has spent much of its three-decade history developing drugs that ended up at other companies via partnerships or licensing deals, is now building up its own pipeline through a $1.7 billion acquisition of Constellation Pharmaceuticals.
Constellation will bring to MorphoSys clinical-stage drugs and expertise in epigenetics, the study of turning genes on or off without altering the genetic code. That research has yielded a Phase 3 drug candidate for a rare blood cancer, as well as another compound in mid-stage testing with the potential to bring epigenetics to the
Julianne Malveaux
Dr. Julianne Malveaux is President Emerita of Bennett College for Women. She is an economist, author and commentator whose popular writings have appeared in USA Today, Black Issues in Higher Education, Ms.Magazine, Essence Magazine, The Progressive, among other publications.
Well-known for appearances on national network programs, including CNN, BET, PBS, NBC, ABC, Fox News, MSNBC, CNBC, C-SPAN and others; Malveaux is booked to offer commentary on subjects ranging from economics to women s rights and public policy. She has also hosted television and radio programs.
A committed activist and civic leader, Dr. Malveaux has held positions in women’s, civil rights, and policy organizations. Currently she serves on the boards of the Economic Policy Institute, The Recreation Wish List Committee of Washington, DC, and the Liberian Education Trust. Malveaux is also President of PUSH Excel, the educational branch of the Rainbow PUSH Coalition.